CD274 and neoplasm: This PD-1 expression is a requirement for the effects of Nivolumab (Supplementary Figure S1), since the main mechanism of action of anti-PD-1 therapy is blocking the interaction between PD-1 on T cells and PD-L1 on tumor cells or stromal cells [26].